Medical tourism is an industry in rude health. Increasing numbers of people around the world are travelling abroad for treatment, lured by lower costs, shorter waiting times and higher standards. Around 77,000 UK patients went overseas in 2006, up 30% on the previous year, according to the International Passenger Survey, while top destinations such as Singapore and Thailand have seen foreign patient numbers rise by 20% annually in recent years.
So how can you profit from this? The best region is Asia. India, Singapore and Thailand offer many large, quoted hospital groups, making it possible to invest directly in the providers. They also have expertise in complex, higher-margin treatment such as cancer, heart surgery and transplants, and benefit from governments that are very keen to encourage this new money-spinner.
Singapore is the easiest market for UK investors to access. The first is Parkway Holdings (SP:PWAY), which runs hospitals and clinics in Singapore, Malaysia, China and Brunei; the Singapore hospitals account for around 50% of its revenues and around 50% of patients in them come from abroad. It also has a joint venture on a hospital in Kolkata with India's Apollo Hospitals and will be building a second one at Mumbai. On a forecast pe ratio of 22.5 times and a dividend yield of 3.8%, Parkway is attractively priced, but, on the downside, sentiment is against the stock at present.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Parkway recently completed a rights issue to fund expansion and repay some short-term debt. This looks prudent, but it has not been well received by the market, especially given that some investors already felt that it had overpaid for a new hospital site in Singapore. It still looks an appealing long-term buy, but there is a risk of share-price weakness in the near future.
Shares in Raffles Medical Group (SP:RFMD), on the other hand, have held up better. The firm operates the Raffles Hospital in Singapore, which accounts for around 55% of its revenues (the remainder comes from clinics in Hong Kong and Singapore) and around 35% of hospital patients come from abroad. There is scope to expand patient numbers in its Singapore facility and it is also looking at international expansion options. On a forward p/e of 22.4 times and a dividend yield of 1.9%, the stock represents good value given its growth potential.
Cris Sholto Heaton is an investment analyst and writer who has been contributing to MoneyWeek since 2006 and was managing editor of the magazine between 2016 and 2018. He is especially interested in international investing, believing many investors still focus too much on their home markets and that it pays to take advantage of all the opportunities the world offers. He often writes about Asian equities, international income and global asset allocation.
Cris began his career in financial services consultancy at PwC and Lane Clark & Peacock, before an abrupt change of direction into oil, gas and energy at Petroleum Economist and Platts and subsequently into investment research and writing. In addition to his articles for MoneyWeek, he also works with a number of asset managers, consultancies and financial information providers.
He holds the Chartered Financial Analyst designation and the Investment Management Certificate, as well as degrees in finance and mathematics. He has also studied acting, film-making and photography, and strongly suspects that an awareness of what makes a compelling story is just as important for understanding markets as any amount of qualifications.
High-street banks continue to offer poor savings rates – is your cash better off with a smaller provider?
Despite numerous warnings by the Financial Conduct Authority (FCA), savers are still being ripped off with low returns on high-street bank savings accounts. How much can your cash earn in a small bank?
By Vaishali Varu Published
Nvidia becomes the fourth biggest company in the world - should you invest?
Chipmaker Nvidia is riding the AI wave, and has overtaken Alphabet and Amazon in terms of market capitalisation. Have new investors missed the boat, or will the share price soar higher?
By Ruth Emery Published